Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

The Role of Magnetic Resonance Elastography in the Diagnosis of Noncirrhotic Portal Hypertension.

Navin PJ, Gidener T, Allen AM, Yin M, Takahashi N, Torbenson MS, Kamath PS, Ehman RL, Venkatesh SK.

Clin Gastroenterol Hepatol. 2019 Oct 17. pii: S1542-3565(19)31162-0. doi: 10.1016/j.cgh.2019.10.018. [Epub ahead of print]

PMID:
31629882
2.

Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study.

Allen AM, Therneau TM, Mara KC, Larson JJ, Watt KD, Hayes SN, Kamath PS.

Am J Gastroenterol. 2019 Nov;114(11):1764-1771. doi: 10.14309/ajg.0000000000000401.

PMID:
31577570
3.

The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.

Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM.

J Hepatol. 2019 Dec;71(6):1229-1236. doi: 10.1016/j.jhep.2019.08.018. Epub 2019 Aug 27.

PMID:
31470068
4.

Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.

Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR.

Hepatology. 2019 Jul 15. doi: 10.1002/hep.30858. [Epub ahead of print]

PMID:
31309602
5.

Reply.

Allen AM, Talwalkar JA, McCoy RG.

Hepatology. 2019 Oct;70(4):1493-1494. doi: 10.1002/hep.30796. No abstract available.

PMID:
31152591
6.

Characterizing specific subgroups in patients with NAFLD: overweight vs obese phenotype.

Martín Mateos R, Allen AM.

Rev Esp Enferm Dig. 2019 Apr;111(4):253-255. doi: 10.17235/reed.2019.6269/2019.

7.

The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.

Allen AM, Shah VH, Therneau TM, Venkatesh SK, Mounajjed T, Larson JJ, Mara KC, Schulte PJ, Kellogg TA, Kendrick ML, McKenzie TJ, Greiner SM, Li J, Glaser KJ, Wells ML, Chen J, Ehman RL, Yin M.

Hepatology. 2018 Dec 24. doi: 10.1002/hep.30483. [Epub ahead of print]

PMID:
30582669
8.

Comparative Expression of Renin-Angiotensin Pathway Proteins in Visceral Versus Subcutaneous Fat.

Zhang Y, Somers KR, Becari C, Polonis K, Pfeifer MA, Allen AM, Kellogg TA, Covassin N, Singh P.

Front Physiol. 2018 Oct 10;9:1370. doi: 10.3389/fphys.2018.01370. eCollection 2018.

9.

Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation.

Narayanan P, Mara K, Izzy M, Dierkhising R, Heimbach J, Allen AM, Watt KD.

Transplantation. 2019 Jan;103(1):e14-e21. doi: 10.1097/TP.0000000000002317.

PMID:
29994981
10.

Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.

Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG.

Hepatology. 2018 Dec;68(6):2230-2238. doi: 10.1002/hep.30094. Epub 2018 Sep 20.

11.

Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation.

Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, Kamath PS, Therneau TM.

Transplantation. 2018 Oct;102(10):1710-1716. doi: 10.1097/TP.0000000000002196.

12.

Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study.

Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS.

Hepatology. 2018 May;67(5):1726-1736. doi: 10.1002/hep.29546. Epub 2018 Mar 23.

13.

Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.

Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD.

Hepatology. 2017 Dec;66(6):2055-2065. doi: 10.1002/hep.29420. Epub 2017 Oct 30. Review.

PMID:
28777879
14.

Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.

Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ, Roberts LR, Heimbach JA, Leise MD.

Clin Gastroenterol Hepatol. 2017 May;15(5):767-775.e3. doi: 10.1016/j.cgh.2016.11.034. Epub 2016 Dec 21.

15.

Time trends in the health care burden and mortality of acute on chronic liver failure in the United States.

Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS.

Hepatology. 2016 Dec;64(6):2165-2172. doi: 10.1002/hep.28812. Epub 2016 Oct 20.

PMID:
27696493
16.

Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure.

Allen AM, Kim WR.

Semin Liver Dis. 2016 May;36(2):123-6. doi: 10.1055/s-0036-1583201. Epub 2016 May 12. Review.

PMID:
27172353
17.

Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival.

Malhi H, Allen AM, Watt KD.

Curr Opin Organ Transplant. 2016 Apr;21(2):99-106. doi: 10.1097/MOT.0000000000000283. Review.

18.

The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study.

Allen AM, Kim WR, Larson JJ, Rosedahl JK, Yawn BP, McKeon K, Hay JE.

Clin Gastroenterol Hepatol. 2016 Feb;14(2):287-94.e1-2. doi: 10.1016/j.cgh.2015.08.022. Epub 2015 Aug 21.

19.

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

Singh S, Khera R, Allen AM, Murad MH, Loomba R.

Hepatology. 2015 Nov;62(5):1417-32. doi: 10.1002/hep.27999. Epub 2015 Oct 1. Review.

PMID:
26189925
20.

Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients.

Allen AM, Kim WR, Larson JJ, Colby C, Therneau TM, Rule AD.

Transplantation. 2015 Jul;99(7):1431-5. doi: 10.1097/TP.0000000000000552.

Supplemental Content

Loading ...
Support Center